Viragen and Valentis to develop HCV compound

PolyMASC, a wholly owned subsidiary of VLTS, will use its protoMASC PEGylation process to deliver VRA's Omniferon, a natural alpha interferon in Phase II trials in Europe for hepatitis C virus. ...